These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7209417)

  • 1. An evaluation of serum protein profiles in the long-term surveillance of prostatic cancer.
    Trautner K; Cooper EH; Haworth S; Ward AM
    Scand J Urol Nephrol; 1980; 14(2):143-9. PubMed ID: 7209417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer].
    Arai Y; Yoshki T; Okada K; Yoshida O; Yamamoto N; Sakatoku J; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 1989 Sep; 35(9):1519-28. PubMed ID: 2479237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute phase reactant proteins in prostatic cancer.
    Ward AM; Cooper EH; Houghton AL
    Br J Urol; 1977 Oct; 49(5):411-8. PubMed ID: 73395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [gamma-Seminoprotein in serum of prostatic cancer].
    Fuse H; Masukagami T; Kataumi Z; Shimazaki J
    Hinyokika Kiyo; 1985 Jan; 31(1):81-5. PubMed ID: 3993497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum proteins of patients with benign hyperplastic and malignant prostate.
    Dhar NK; Dube PC; Chowdhury AR; Kar AB
    Indian J Cancer; 1973 Jun; 10(2):188-90. PubMed ID: 4129821
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk factors for coronary heart disease and acute-phase proteins. A population-based study.
    Danesh J; Muir J; Wong YK; Ward M; Gallimore JR; Pepys MB
    Eur Heart J; 1999 Jul; 20(13):954-9. PubMed ID: 10361047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum proteins in patients with benign and malignant diseases of the prostate.
    Ablin RJ; Soanes WA; Bronson PM; Gonder MJ
    Neoplasma; 1971; 18(3):271-6. PubMed ID: 4106139
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prostatic cancer: indications for hormone therapy].
    Bruntsch U; Gallmeier WM
    MMW Munch Med Wochenschr; 1979 Mar; 121(9):300-2. PubMed ID: 85258
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diagnosis and therapy of prostatic carcinoma].
    Vahlensieck W; Tümmers H; Tschischak D
    Fortschr Med; 1974 Oct; 92(30):1195-8. PubMed ID: 4138473
    [No Abstract]   [Full Text] [Related]  

  • 10. [Serum testosterone and acid phosphatase levels in patients with prostatic cancer treated with Estracyt].
    Németh A; Morvay J; Vécsei B
    Orv Hetil; 1981 Apr; 122(17):1017-20. PubMed ID: 7022313
    [No Abstract]   [Full Text] [Related]  

  • 11. The relationship among acute-phase responce proteins, cytokines, and hormones in various gastrointestinal cancer types patients with cachectic.
    Kemik O; Kemik AS; Begenik H; Erdur FM; Emre H; Sumer A; Purisa S; Tuzun S; Kotan C
    Hum Exp Toxicol; 2012 Feb; 31(2):117-25. PubMed ID: 21803781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contribution to the biochemical diagnosis of prostatic cancer].
    Romero-Aguirre F
    J Urol Nephrol (Paris); 1969 Mar; 75(3):191-8. PubMed ID: 4182924
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
    Kerle D; Williams G; Ware H; Doble A; Allen J; Bloom SR
    Br J Urol; 1984 Oct; 56(5):495-8. PubMed ID: 6242022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Importance of serum acid phosphatase for the prognosis of prostatic carcinoma].
    Breitwieser P; Nöske HD
    Z Urol Nephrol; 1971 Apr; 64(4):249-56. PubMed ID: 5094006
    [No Abstract]   [Full Text] [Related]  

  • 15. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dynamics of tumor markers in prostatic cancer].
    Matsuda M; Tada Y; Nakano E; Sonoda T; Miyamoto T
    Rinsho Byori; 1986 Jul; 34 Spec No 68():98-105. PubMed ID: 2428999
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recurring thrombosis of the subclavian vein during estrogen therapy of prostatic cancer].
    Fischer H; Wambach G
    Dtsch Med Wochenschr; 1984 Nov; 109(45):1725-7. PubMed ID: 6499670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oestrogen therapy in prostatic cancer.
    Smith PH; Akdas A
    Scand J Urol Nephrol Suppl; 1980; 55():91-4. PubMed ID: 6938043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oestrogen therapy and serum cortisol in carcinoma of the prostate.
    Morales A; Kraus AS; Bruce AW
    Br J Urol; 1975 Jun; 47(3):283-6. PubMed ID: 1095102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The significance of serum gamma-seminoprotein in prostatic cancer].
    Ishikawa S; Tozuka K; Ishiyama S; Goto K; Ohba S; Tokue A; Yonese Y; Kamachi S; Sakurabayashi I; Kawai T
    Hinyokika Kiyo; 1985 Jun; 31(6):961-7. PubMed ID: 2414979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.